Agastiya Biotech is developing cancer therapies by identifying and targeting critical pathways involved in tumor growth and metastasis. The company is particularly interested in addressing the unmet medical needs of patients with pancreatic cancer and acute myeloid leukemia (AML). Agastiya Biotech is developing a novel small molecule drug, AB-001, which inhibits PD-L1 and also targets intracellular signaling pathways within the tumor microenvironment. This dual mechanism of action has shown promise in preclinical studies across multiple cancer types, including solid and liquid tumors.

Agastiya Biotech

Founded: 2019
Location: Temecula, California
Employee range: 1 - 50
Clinical stage: Clin3
Therapy area: Psoriasis
Drug types: DRM, IMM, ONC, END, INF
Lead product: PS35 (licensed to Lupin Pharmaceuticals)
Funding: not disclosed

Drug notes:

About:

Jobs: